FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 362 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75 September 17, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Load more HOT NEWS ESMO Gastrointestinal Cancers Congress 2025, Barcelona, Spain, 2-5 July 如果您剛確診為肺癌患者，請來看看專家的回答 Addressing the Barriers to Minority Participation in Cancer Clinical Trials Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal...
